Business
Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency
80% plasma arginine reduction (primary endpoint; p 90.5% of patients achieved normal plasma arginine levels Pegzilarginase was well-tolerated; no
About this update from Spyre Therapeutics, Inc.
[{"type":"text","content":"80% plasma arginine reduction (primary endpoint; p \n 90.5% of patients achieved normal plasma arginine levels\n Pegzilarginase was well-tolerated; no discontinuations due to adverse events\n First potential therapy to address key driver of ARG1-D, a devastating ultra-rare disease\n Plan to submit BLA in first half of 2022\n Company to host conference call and webcast today at 8:00am EST\n\n\nAUSTIN, Texas, Dec. 6, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the pivotal Phase 3 study, PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints), met the primary endpoint with a statistically significant reduction in plasma arginine from baseline after 24 weeks of treatment with pegzilarginase (p","length":1200,"tagName":"div"}]